Genscript Biotech Corporation (GNNSF)
USD 1.5
(-21.0%)
USD 1.5
(-21.0%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 839.52 Million USD | 34.49% |
| 2022 | 625.69 Million USD | 22.43% |
| 2021 | 511.06 Million USD | 30.76% |
| 2020 | 390.84 Million USD | 42.98% |
| 2019 | 273.35 Million USD | 18.33% |
| 2018 | 231.01 Million USD | 51.34% |
| 2017 | 152.64 Million USD | 33.04% |
| 2016 | 114.73 Million USD | 32.32% |
| 2015 | 86.7 Million USD | 23.88% |
| 2014 | 69.99 Million USD | 16.45% |
| 2013 | 60.1 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 280.68 Million USD | 0.0% |
| 2024 Q1 | 280.68 Million USD | -37.45% |
| 2023 Q2 | 391.3 Million USD | 100.0% |
| 2023 Q1 | 195.65 Million USD | -39.23% |
| 2023 FY | 841.49 Million USD | 34.49% |
| 2023 Q4 | 448.71 Million USD | 100.22% |
| 2023 Q3 | 224.1 Million USD | -42.73% |
| 2022 Q3 | 158.05 Million USD | -47.97% |
| 2022 Q2 | 303.76 Million USD | 96.24% |
| 2022 Q1 | 154.79 Million USD | -44.91% |
| 2022 FY | 625.69 Million USD | 22.43% |
| 2022 Q4 | 321.97 Million USD | 103.71% |
| 2021 Q4 | 280.96 Million USD | 115.69% |
| 2021 Q1 | 114.78 Million USD | -48.84% |
| 2021 FY | 511.06 Million USD | 30.76% |
| 2021 Q3 | 130.26 Million USD | -43.22% |
| 2021 Q2 | 229.43 Million USD | 99.89% |
| 2020 Q4 | 224.37 Million USD | 99.93% |
| 2020 Q2 | 166.62 Million USD | 100.27% |
| 2020 Q1 | 83.19 Million USD | -45.33% |
| 2020 FY | 390.84 Million USD | 42.98% |
| 2020 Q3 | 112.22 Million USD | -32.65% |
| 2019 Q3 | 75.73 Million USD | -38.1% |
| 2019 Q4 | 152.17 Million USD | 100.92% |
| 2019 FY | 273.35 Million USD | 18.33% |
| 2019 Q1 | 60.93 Million USD | 2.59% |
| 2019 Q2 | 122.35 Million USD | 100.78% |
| 2018 Q3 | 59.39 Million USD | 5.86% |
| 2018 Q2 | 56.11 Million USD | 0.0% |
| 2018 Q4 | 59.39 Million USD | 0.0% |
| 2018 Q1 | 56.11 Million USD | 25.72% |
| 2018 FY | 231.01 Million USD | 51.34% |
| 2017 Q3 | 44.63 Million USD | 40.82% |
| 2017 FY | 152.64 Million USD | 33.04% |
| 2017 Q4 | 44.63 Million USD | 0.0% |
| 2017 Q2 | 31.69 Million USD | 0.0% |
| 2017 Q1 | 31.69 Million USD | 3.01% |
| 2016 Q1 | 26.6 Million USD | 16.52% |
| 2016 FY | 114.73 Million USD | 32.32% |
| 2016 Q4 | 30.76 Million USD | 0.0% |
| 2016 Q3 | 30.76 Million USD | 15.67% |
| 2016 Q2 | 26.6 Million USD | 0.0% |
| 2015 Q3 | 22.82 Million USD | 11.23% |
| 2015 Q1 | 20.52 Million USD | 12.55% |
| 2015 Q4 | 22.82 Million USD | 0.0% |
| 2015 FY | 86.7 Million USD | 23.88% |
| 2015 Q2 | 20.52 Million USD | 0.0% |
| 2014 Q1 | 16.76 Million USD | 0.0% |
| 2014 FY | 69.99 Million USD | 16.45% |
| 2014 Q4 | 18.23 Million USD | 0.0% |
| 2014 Q3 | 18.23 Million USD | 8.81% |
| 2014 Q2 | 16.76 Million USD | 0.0% |
| 2013 FY | 60.1 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 75.72 Thousand USD | -1108569.642% |
| Evofem Biosciences, Inc. | 18.21 Million USD | -4508.239% |
| Nascent Biotech, Inc. | - USD | -Infinity% |
| Rebus Holdings, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 122.95 Million USD | -582.8% |
| Qrons Inc. | - USD | -Infinity% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 1.93 Million USD | -43353.882% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Skye Bioscience, Inc. | - USD | -Infinity% |
| Eiger BioPharmaceuticals, Inc. | 15.77 Million USD | -5222.57% |
| Nanobac Pharmaceuticals, Incorporated | 17.62 Thousand USD | -4764266.381% |
| Institute of Biomedical Research Corp. | - USD | -Infinity% |
| SQZ Biotechnologies Company | 21.47 Million USD | -3808.786% |
| Intellipharmaceutics International Inc. | 65.72 Thousand USD | -1277177.568% |
| Propanc Biopharma, Inc. | - USD | -Infinity% |
| Mesoblast Limited | 5.9 Million USD | -14124.483% |
| Marizyme, Inc. | 645.81 Thousand USD | -129896.284% |
| Genus plc | 668.8 Million USD | -25.528% |
| VioQuest Pharmaceuticals, Inc. | - USD | -Infinity% |
| Pharming Group N.V. | 245.31 Million USD | -242.223% |
| Therapeutic Solutions International, Inc. | 98.99 Thousand USD | -847960.489% |
| CNBX Pharmaceuticals Inc. | 410.16 Thousand USD | -204580.799% |
| Nymox Pharmaceutical Corporation | - USD | -Infinity% |
| ContraFect Corporation | - USD | -Infinity% |
| PsyBio Therapeutics Corp. | - USD | -Infinity% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 76.76 Thousand USD | -1093592.109% |
| IMV Inc. | - USD | -Infinity% |
| AXIM Biotechnologies, Inc. | 39.51 Thousand USD | -2124321.782% |
| MultiCell Technologies, Inc. | 49.32 USD | -1702207929.197% |
| ONE Bio Corp. | 52.29 Million USD | -1505.335% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 49.72 Million USD | -1588.48% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 48.9 Thousand USD | -1716728.221% |
| Q BioMed Inc. | 284.35 Thousand USD | -295142.868% |
| Emmaus Life Sciences, Inc. | 29.59 Million USD | -2736.534% |
| Mosaic ImmunoEngineering Inc. | - USD | -Infinity% |
| Biomind Labs Inc. | - USD | -Infinity% |
| American Oriental Bioengineering, Inc. | 145.09 Million USD | -478.588% |
| Provectus Biopharmaceuticals, Inc. | 557.71 Thousand USD | -150431.459% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 70 Thousand USD | -1199227.143% |
| GlobeStar Therapeutics Corporation | - USD | -Infinity% |
| THC Farmaceuticals, Inc. | - USD | -Infinity% |
| Acro Biomedical Co., Ltd. | 658.5 Thousand USD | -127391.116% |
| Curative Biotechnology, Inc. | - USD | -Infinity% |
| GB Sciences, Inc. | - USD | -Infinity% |
| Alpha Cognition Inc. | - USD | -Infinity% |
| HST Global, Inc. | - USD | -Infinity% |
| CSL Limited | 14.69 Billion USD | 94.285% |
| Wesana Health Holdings Inc. | - USD | -Infinity% |
| Halberd Corporation | 999.00 USD | -84036836.937% |
| Enzolytics Inc. | 52.79 Thousand USD | -1590037.51% |
| Agentix Corp. | - USD | -Infinity% |
| Resverlogix Corp. | - USD | -Infinity% |
| Nuo Therapeutics, Inc. | 608.52 Thousand USD | -137861.3% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.22 Billion USD | 31.541% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 140.24 Thousand USD | -598528.799% |
| RespireRx Pharmaceuticals Inc. | - USD | -Infinity% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | 617.38 Thousand USD | -135881.658% |
| Zenith Capital Corp. | - USD | -Infinity% |
| Ember Therapeutics, Inc. | - USD | -Infinity% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | - USD | -Infinity% |
| WPD Pharmaceuticals Inc. | - USD | -Infinity% |
| Cotinga Pharmaceuticals Inc. | - USD | -Infinity% |
| Kadimastem Ltd | - USD | -Infinity% |
| Helix BioMedix, Inc. | 997.72 Thousand USD | -84044.244% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 48.35 Million USD | -1636.214% |
| BioStem Technologies, Inc. | 16.68 Million USD | -4931.517% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | - USD | -Infinity% |
| LadRx Corporation | - USD | -Infinity% |
| Cell Source, Inc. | - USD | -Infinity% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -354790.514% |
| Regen BioPharma, Inc. | 236.56 Thousand USD | -354790.514% |
| NovAccess Global Inc. | - USD | -Infinity% |
| Affymax, Inc. | 1.36 Million USD | -61224.251% |
| Itoco Inc. | - USD | -Infinity% |
| Rasna Therapeutics, Inc. | - USD | -Infinity% |
| Pathfinder Cell Therapy, Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | - USD | -Infinity% |
| CytoDyn Inc. | - USD | -Infinity% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 473.73 Thousand USD | -177116.769% |
| SYBLEU INC | 11.69 Thousand USD | -7177815.527% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | - USD | -Infinity% |
| International Stem Cell Corporation | 7.78 Million USD | -10678.393% |
| Bioxytran, Inc. | - USD | -Infinity% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | - USD | -Infinity% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | - USD | -Infinity% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 13 Thousand USD | -6457815.385% |
| Adhera Therapeutics, Inc. | - USD | -Infinity% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | - USD | -Infinity% |
| Innovation Pharmaceuticals Inc. | - USD | -Infinity% |
| Neutra Corp. | 39.53 Thousand USD | -2123461.997% |
| Windtree Therapeutics, Inc. | - USD | -Infinity% |
| PureTech Health plc | 3.33 Million USD | -25111.081% |
| Coeptis Therapeutics, Inc. | - USD | -Infinity% |
| IXICO plc | 6.66 Million USD | -12496.084% |
| IntelGenx Technologies Corp. | 1.03 Million USD | -80701.636% |
| Gelesis Holdings, Inc. | 25.76 Million USD | -3158.156% |
| CSL Limited | 14.8 Billion USD | 94.328% |
| Cellectis S.A. | 755 Thousand USD | -111095.894% |